Your browser doesn't support javascript.
loading
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Matissek, Stephan J; Han, Weiguo; Karbalivand, Mona; Sayed, Mohamed; Reilly, Brendan M; Mallat, Shayna; Ghazal, Shimaa M; Munshi, Manit; Yang, Guang; Treon, Steven P; Walker, Sarah R; Elsawa, Sherine F.
Afiliação
  • Matissek SJ; Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
  • Han W; Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
  • Karbalivand M; Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
  • Sayed M; Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
  • Reilly BM; Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
  • Mallat S; Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
  • Ghazal SM; Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH, 03824, USA.
  • Munshi M; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Yang G; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.
  • Treon SP; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Walker SR; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA.
  • Elsawa SF; Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Epigenomics ; 13(2): 129-144, 2021 01.
Article em En | MEDLINE | ID: mdl-33356554
ABSTRACT

Aim:

Waldenström macroglobulinemia (WM) is a low-grade B-cell lymphoma characterized by overproduction of monoclonal IgM. To date, there are no therapies that provide a cure for WM patients, and therefore, it is important to explore new therapies. Little is known about the efficiency of epigenetic targeting in WM. Materials &

methods:

WM cells were treated with BET inhibitors (JQ1 and I-BET-762) and venetoclax, panobinostat or ibrutinib.

Results:

BET inhibition reduces growth of WM cells, with little effect on survival. This finding was enhanced by combination therapy, with panobinostat (LBH589) showing the highest synergy.

Conclusion:

Our studies identify BET inhibitors as effective therapy for WM, and these inhibitors can be enhanced in combination with BCL2 or histone deacetylase inhibition.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Macroglobulinemia de Waldenstrom / Receptores de Superfície Celular / Proteínas Proto-Oncogênicas c-bcl-2 / Epigênese Genética / Inibidores de Histona Desacetilases / Proteínas do Tecido Nervoso / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Epigenomics Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Macroglobulinemia de Waldenstrom / Receptores de Superfície Celular / Proteínas Proto-Oncogênicas c-bcl-2 / Epigênese Genética / Inibidores de Histona Desacetilases / Proteínas do Tecido Nervoso / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Epigenomics Ano de publicação: 2021 Tipo de documento: Article